Bispecific antibody · Immune activation, directed at epidermal growth factor receptor (EGFR) and CD3 (CD3E) · developed by CytomX Therapeutics
CX-904 is a protease-activated bispecific antibody prodrug that binds EGFR on tumor cells and CD3 on cytotoxic T-lymphocytes once a masking peptide is cleaved by tumor-associated proteases. It redirects T cells to kill EGFR-expressing cells and is being studied in solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05387265 | Phase 1 | Solid Tumors | Terminated | CTMX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Solid Tumors
Updated Nov 8, 2026. Something wrong or missing? Report it on the CTMX page.
See CTMX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CTMX catalysts and pipeline →